Federal Circuit Affirms Obviousness: Merck Serono’s Cladribine MS Patents Invalidated

Introduction

In a significant blow to pharmaceutical patent protection in the multiple sclerosis treatment space, the U.S. Court of Appeals for the Federal Circuit affirmed the Patent Trial and Appeal Board’s (PTAB) determination that Merck Serono SA’s patents covering a cladribine dosing regimen for multiple sclerosis (MS) are unpatentable due to obviousness. Case No. 25-1210, closed October 30, 2025, after 339 days of appellate proceedings, underscores the enduring power of prior art combinations to defeat pharmaceutical method patents—even those protecting commercially significant treatment regimens.

The ruling, which affirmed that the combination of two prior art references (Bodor and Stelmasiak) rendered all claims at issue obvious, carries material implications for pharmaceutical patent prosecution strategy, inter partes review (IPR) defense planning, and freedom-to-operate (FTO) assessments in the competitive MS drug market. For patent attorneys, IP professionals, and R&D teams navigating biopharmaceutical patent litigation, this case offers critical procedural and strategic lessons.

Case Overview

The Parties

The Patent at Issue

This case centered on U.S. Patent No. US7713947B2 (Application No. US11/722018), a pharmaceutical method patent covering a specific cladribine dosing regimen for treating relapsing forms of multiple sclerosis. The asserted claims describe a defined cumulative dose schedule for oral cladribine administration targeting MS patients—a regimen distinguished from prior cladribine uses by its structured, weight-based dosing approach.

Legal Representation

Plaintiff (Merck Serono): WilmerHale (David B. Bassett, Emily R. Whelan, Mark Christopher Fleming, and team)

Defendant (Hopewell Pharma): Sterne, Kessler, Goldstein & Fox PLLC (John Christopher Rozendaal, Eldora Ellison Ph.D., Chandrika Vira, and team)

Both firms bring substantial pharmaceutical patent litigation experience, with Sterne Kessler’s scientific expertise—reflected in Dr. Eldora Ellison’s Ph.D. credentials—particularly relevant in technically complex obviousness challenges.

Litigation Timeline & Procedural History

The dispute originated at the PTAB, where Hopewell Pharma initiated an invalidity/cancellation action targeting US7713947B2 on patentability grounds. The Board sided with Hopewell, finding the claims unpatentable based on prior art. Merck Serono appealed to the Court of Appeals for the Federal Circuit—the exclusive appellate court for U.S. patent matters—seeking reversal of the PTAB’s obviousness determination.

The 339-day appellate timeline is consistent with Federal Circuit norms for pharmaceutical patent appeals involving detailed technical records. The Washington, D.C. Circuit venue reflects the Federal Circuit’s jurisdictional seat over all patent appeals from the USPTO and PTAB. No chief judge assignment data was disclosed in the available case record.

The Verdict & Legal Analysis

Outcome

The Federal Circuit affirmed the PTAB’s determination that:

• • The Bodor six-line disclosure constitutes qualifying prior art to the patents-in-suit; and
• • The combination of Bodor and Stelmasiak renders all claims at issue obvious under 35 U.S.C. § 103.

The court’s one-word conclusion—”AFFIRMED”—signals clear agreement with the Board’s factual findings and legal reasoning, leaving Merck Serono’s patent on the asserted cladribine regimen invalid and unenforceable. No damages were at issue given the nature of the invalidity/cancellation proceeding.

Verdict Cause Analysis: Obviousness Under § 103

The core legal question was whether prior art—specifically the Bodor reference’s six-line disclosure combined with Stelmasiak—would have rendered the claimed cladribine dosing regimen obvious to a person of ordinary skill in the art (POSITA) at the relevant time.

The Bodor Prior Art Dispute: A central battleground was whether the Bodor reference’s brief six-line disclosure qualified as prior art to the patents-in-suit. Merck Serono apparently challenged this characterization, but the Federal Circuit affirmed the Board’s finding that it did. This holding is noteworthy: even a minimally detailed prior art disclosure can anchor an obviousness combination if it teaches the relevant concept, however briefly.

The Bodor-Stelmasiak Combination: The Federal Circuit agreed that a POSITA would have been motivated to combine Bodor’s teaching with Stelmasiak’s cladribine-related disclosures, and that the combination would have produced a reasonable expectation of success in arriving at the claimed dosing regimen. This reflects the *KSR International Co. v. Teleflex Inc.* framework, under which courts broadly assess whether combining known elements in the prior art yields predictable results.

Pharmaceutical Dosing as Obviousness Territory: The ruling reinforces a challenging reality for pharmaceutical patent holders: when a drug compound is known and prior art discloses related dosing approaches—even in summary form—optimizing or structuring a regimen may not constitute a non-obvious inventive step. Method-of-treatment claims built around dosing schedules for previously known compounds face heightened obviousness scrutiny.

Legal Significance

This decision carries precedential weight for several reasons:

• • Minimal prior art disclosures count: The affirmance that Bodor’s six-line passage qualifies as prior art signals the Federal Circuit’s willingness to credit sparse disclosures, provided they teach the relevant concept.
• • Combination obviousness in pharma: The ruling reinforces that combining two prior art references covering a known drug compound and a related treatment application can defeat even commercially established pharmaceutical patents.
• • PTAB deference on appeal: The Federal Circuit’s clean affirmance reflects substantial deference to PTAB factual findings under the substantial evidence standard—a consistent appellate posture that makes PTAB victories difficult to overturn.

Strategic Takeaways

For Patent Holders (Pharmaceutical Companies):

• • Draft claims with layered specificity—consider unexpected results, synergistic effects, or clinical superiority data to distinguish from prior art combinations
• • Anticipate PTAB challenges to dosing-method patents during prosecution; build a robust file history addressing known prior art
• • Post-grant prosecution counsel should proactively evaluate combination obviousness risks before commercial launch

For Accused Infringers and PTAB Petitioners:

• • Brief but substantive prior art disclosures can anchor successful IPR petitions—exhaustive single-reference novelty arguments are not required
• • A technically credentialed legal team (note Dr. Ellison’s involvement) strengthens the scientific narrative in highly technical pharmaceutical IPRs

For R&D Teams:

• • FTO analyses must account for prior art combinations, not just individual references
• • Investment in clinical differentiation data (e.g., superiority studies) may support “unexpected results” arguments to rebut obviousness during prosecution

Industry & Competitive Implications

The Federal Circuit’s ruling in *Merck Serono v. Hopewell Pharma* arrives against a backdrop of intensifying patent challenges in the MS therapeutics market. Cladribine-based therapy, commercialized as Mavenclad® in oral form, competes with a crowded field of disease-modifying therapies. The invalidation of US7713947B2 may open a pathway for competitors or generic manufacturers exploring cladribine dosing regimens without licensing obligations tied to this patent.

More broadly, the case reflects the continued effectiveness of PTAB inter partes review as a pharmaceutical patent-clearing mechanism. Since *Oil States Energy Services v. Greene’s Energy Group* (2018) confirmed PTAB’s constitutionality, post-grant challenges have remained a strategic weapon for competitors facing branded pharmaceutical barriers.

For companies holding portfolios of pharmaceutical method patents—particularly those defining dosing regimens for known compounds—this ruling is a call to audit patent strength against combination prior art theories. Licensing strategies in the MS space may shift as this and related patents face validity scrutiny.

FAQ

What patents were involved in *Merck Serono v. Hopewell Pharma*?

The case centered on U.S. Patent No. 7,713,947 B2 (Application No. US11/722018), covering a cladribine dosing regimen for treating multiple sclerosis.

What was the basis for invalidation in this case?

The Federal Circuit affirmed the PTAB’s finding that the combination of the Bodor prior art reference and the Stelmasiak reference rendered all asserted claims obvious under 35 U.S.C. § 103, making the patent unpatentable.

How might this verdict affect pharmaceutical patent litigation?

The ruling reinforces that brief prior art disclosures can support combination obviousness challenges to pharmaceutical dosing patents, potentially encouraging more PTAB petitions against method-of-treatment claims for known compounds.

*For primary source documents, consult the USPTO Patent Center for US7713947B2 and the Federal Circuit’s public docket for Case No. 25-1210.*
*Explore related Federal Circuit pharmaceutical patent decisions on the Court’s official opinions database.*